[
    [
        {
            "time": "",
            "original_text": "股获买入评级 最新:贝达药业",
            "features": {
                "keywords": [
                    "贝达药业",
                    "买入评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "股获买入评级 最新:贝达药业",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "益方生物答科创板二轮问询，专利纠纷和商业秘密纠纷等被关注",
            "features": {
                "keywords": [
                    "益方生物",
                    "科创板",
                    "专利纠纷",
                    "商业秘密纠纷"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "益方生物答科创板二轮问询，专利纠纷和商业秘密纠纷等被关注",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "26家药企上半年八成净利润增长 两家公司重磅新药即将报产",
            "features": {
                "keywords": [
                    "药企",
                    "净利润增长",
                    "新药报产"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "26家药企上半年八成净利润增长 两家公司重磅新药即将报产",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "西部证券维持贝达药业买入评级，2021年半年报点评：业绩高基数下持续增长，管线取得阶段性进展",
            "features": {
                "keywords": [
                    "西部证券",
                    "贝达药业",
                    "买入评级",
                    "业绩增长",
                    "管线进展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持贝达药业买入评级，2021年半年报点评：业绩高基数下持续增长，管线取得阶段性进展",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]